Anti-PLVAP antibodies have been demonstrated to be effective in regard to treating endotoxin-mediated inflammation [59], pulmonary fibrosis [25], kidney disease [25] and certain retinal diseases [49]. Here, PLVAP is linked to pulmonary fibrosis.